136 assets in B-Cell Acute Lymphoblastic Leukemia

Therapeutic assets addressing B-Cell Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Mesna B-Cell Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P1/2	CCC (52)
mk-1045 B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Siltuximab B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Tyenne B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
cd19/cd22-bispecific car-t cells B-Cell Acute Lymphoblastic Leukemia	Beijing Tongren Hospital	P2	CCC (51)
cd19+cd22 car-t B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Decitabine B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Humax-Cd20 B-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P2	CCC (51)
Revumenib B-Cell Acute Lymphoblastic Leukemia	SWOG Cancer Research Network	P2	CCC (51)
Filgrastim-Sndz B-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P2	CCC (49)
Anti-Cd19 Anti-Cd20 Bispecific Car-T B-Cell Acute Lymphoblastic Leukemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1/2	CCC (48)
Anti-Cd19 Ucar-Nk Cells B-Cell Acute Lymphoblastic Leukemia	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	P1/2	CCC (48)
azd4512 B-Cell Acute Lymphoblastic Leukemia	AstraZeneca	P1/2	CCC (48)
Surovatamig B-Cell Acute Lymphoblastic Leukemia	AstraZeneca	P1/2	CCC (48)
4scar-cd22/cd123/cd38/cd10/cd20/tslpr B-Cell Acute Lymphoblastic Leukemia	Shenzhen Geno-Immune Medical Institute	P1/2	CC (47)
Anti-Cd19 Autologous Car-T Cell Infusion B-Cell Acute Lymphoblastic Leukemia	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	P1/2	CC (47)
Autologous Bcma/Cd19 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Bcma/Gprc5D Dual-Target Car-T B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd22 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cd123 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module B-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (47)
cd22 car-t B-Cell Acute Lymphoblastic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P1/2	CC (47)
Cpx-351 B-Cell Acute Lymphoblastic Leukemia	Children's Oncology Group	P1/2	CC (47)
Imgn632 B-Cell Acute Lymphoblastic Leukemia	Children's Oncology Group	P1/2	CC (47)
Interferon ?1 (Human Fibroblast Protein Moiety) B-Cell Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P1/2	CC (47)
Thiscart19A B-Cell Acute Lymphoblastic Leukemia	Zhejiang University	P1	CC (46)
Autologous Car19 T Lymphocytes B-Cell Acute Lymphoblastic Leukemia	Institute of Hematology and Blood Transfusion, Czech Republic	P1	CC (43)
b019 B-Cell Acute Lymphoblastic Leukemia	Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.	P1	CC (43)
Baffr-Car T Cells B-Cell Acute Lymphoblastic Leukemia	PeproMene Bio, Inc.	P1	CC (43)
Cart22-65S B-Cell Acute Lymphoblastic Leukemia	Stephan Grupp MD PhD	P1/2	CC (43)
CD123-CAR T B-Cell Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P1	CC (43)
cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells B-Cell Acute Lymphoblastic Leukemia	University of Colorado, Denver	P1/2	CC (43)
cd19-il7ra car-t cells B-Cell Acute Lymphoblastic Leukemia	Chulalongkorn University	P1	CC (43)
Clic-2201 B-Cell Acute Lymphoblastic Leukemia	British Columbia Cancer Agency	P1	CC (43)
Clls52 B-Cell Acute Lymphoblastic Leukemia	Cellectis S.A.	P1/2	CC (43)
Cnct19 B-Cell Acute Lymphoblastic Leukemia	Juventas Cell Therapy Ltd.	P1/2	CC (43)
hy004 B-Cell Acute Lymphoblastic Leukemia	Juventas Cell Therapy Ltd.	P1/2	CC (43)
Ipilimumab B-Cell Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P1	CC (43)
Kur-502 B-Cell Acute Lymphoblastic Leukemia	Athenex, Inc.	P1	CC (43)
Lstcar019 B-Cell Acute Lymphoblastic Leukemia	Kunming Hope of Health Hospital	P1/2	CC (43)
Mosunetuzumab B-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P1	CC (43)
Nanobody-Based Cd19/Cd22 Tandem Dual Car-T B-Cell Acute Lymphoblastic Leukemia	Liping Dou	P1/2	CC (43)
pit565 B-Cell Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	P1	CC (43)
Pomalidomide B-Cell Acute Lymphoblastic Leukemia	University of Michigan Rogel Cancer Center	P1	CC (43)
sup19 car-t B-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Tslpr-Cart B-Cell Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P1	CC (43)
Ucart22 B-Cell Acute Lymphoblastic Leukemia	Cellectis S.A.	P1/2	CC (43)

Showing 51 to 100 of 136 assets

PreviousPage 2 of 3Next